Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03382795

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer Clinical Trial

Official title:
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy

Clinical Trial Summary

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy

Clinical Trial Description

This study is designed to be multi-center, open-label, single-arm, prospective, phase II trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients will be enrolled into the trial, and expected study duration is 48 months from Institutional Review Board(IRB) and Korea Ministry of Food and Drug Safety(MFDS) approval date. The study drug will be administered orally as one tablet(Gefitinib 250mg/ Erlotinib 150mg) once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug daily can be reduced according to dose reduction criteria in protocol. A cycle of study treatment is defined as 28 days, and subjects will visit the site every 2 cycles(56 days). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03382795
Study type Interventional
Source Korea University Guro Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 3, 2018
Completion date March 31, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02125240 - Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Phase 3
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Not yet recruiting NCT04643847 - A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases Phase 2
Active, not recruiting NCT03126799 - A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) Phase 2
Recruiting NCT04900935 - Patient-centered, Optimal Integration of Survivorship and Palliative Care N/A
Not yet recruiting NCT02788058 - A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy Phase 2
Recruiting NCT02103257 - Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Phase 4
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Recruiting NCT05037331 - Osimertinib for Advanced EGFR-positive NSCLC Patients
Recruiting NCT04001777 - A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients Phase 1
Active, not recruiting NCT02194556 - Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Phase 4
Recruiting NCT05089916 - Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Phase 2
Not yet recruiting NCT06208033 - SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) Early Phase 1
Completed NCT02729298 - First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT01665417 - Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase 4
Not yet recruiting NCT05962021 - Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation Phase 2
Completed NCT04105153 - Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC